{"id":"thalidomide-plus-dexamethasone","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Thromboembolism"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL426123","moleculeType":"Small molecule","molecularWeight":"258.23"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Thalidomide binds to cereblon (CRBN), promoting degradation of IKZF1 and IKZF3 proteins, which enhances T-cell proliferation and NK cell activation while reducing TNF-α production. Dexamethasone amplifies these effects through glucocorticoid receptor signaling, providing additional anti-inflammatory activity and enhancing apoptosis in malignant cells. This combination is particularly effective in multiple myeloma and other hematologic malignancies.","oneSentence":"Thalidomide acts as an immunomodulatory agent and cereblon E3 ligase ligand, while dexamethasone provides corticosteroid-mediated anti-inflammatory and immunosuppressive effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:38:12.482Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (newly diagnosed or relapsed/refractory)"},{"name":"Light chain myeloma"}]},"trialDetails":[{"nctId":"NCT02844309","phase":"PHASE4","title":"The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-05","conditions":"Waldenström Macroglobulinemia","enrollment":44},{"nctId":"NCT02858804","phase":"PHASE4","title":"EDOCH Alternating With DHAP for New Diagnosed Younger MCL","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-01","conditions":"Mantle Cell Lymphoma","enrollment":55},{"nctId":"NCT00572169","phase":"PHASE3","title":"UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2006-11","conditions":"Multiple Myeloma","enrollment":177},{"nctId":"NCT02461888","phase":"PHASE2","title":"Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2015-12","conditions":"Multiple Myeloma","enrollment":112},{"nctId":"NCT07264894","phase":"PHASE4","title":"ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Zhengzhou University","startDate":"2025-12-31","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":30},{"nctId":"NCT00098475","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-11-03","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":452},{"nctId":"NCT07247097","phase":"PHASE2","title":"ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-04-15","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible","enrollment":160},{"nctId":"NCT07204041","phase":"PHASE2","title":"Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-08-01","conditions":"Langerhans Cell Histiocytosis (LCH)","enrollment":40},{"nctId":"NCT03004287","phase":"PHASE2","title":"2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2017-07-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT01659658","phase":"PHASE3","title":"Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis","status":"TERMINATED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2012-12-26","conditions":"Relapsed or Refractory Systemic Light Chain Amyloidosis","enrollment":177},{"nctId":"NCT05835726","phase":"","title":"Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2022-01-01","conditions":"Multiple Myeloma, Daratumumab, Autologous Stem Cell Transplantation","enrollment":188},{"nctId":"NCT06793475","phase":"NA","title":"Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-04-09","conditions":"Extramedullary Multiple Myeloma","enrollment":20},{"nctId":"NCT03896737","phase":"PHASE2","title":"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2019-04-16","conditions":"Multiple Myeloma","enrollment":401},{"nctId":"NCT00734877","phase":"PHASE3","title":"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-07","conditions":"Multiple Myeloma","enrollment":382},{"nctId":"NCT01998971","phase":"PHASE1","title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-18","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT02541383","phase":"PHASE3","title":"A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Intergroupe Francophone du Myelome","startDate":"2015-09","conditions":"Multiple Myeloma","enrollment":1085},{"nctId":"NCT01539083","phase":"PHASE3","title":"Velcade (Bortezomib) Consolidation After Transplant","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2012-01-13","conditions":"Multiple Myeloma","enrollment":256},{"nctId":"NCT06284395","phase":"","title":"Two Schemes Response in Multiple Myeloma","status":"RECRUITING","sponsor":"Hospital General de Mexico","startDate":"2023-11-20","conditions":"Response, Acute Phase, Survivorship","enrollment":83},{"nctId":"NCT04352205","phase":"PHASE2","title":"Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure","status":"TERMINATED","sponsor":"Emory University","startDate":"2020-05-07","conditions":"Plasma Cell Myeloma, Renal Failure","enrollment":17},{"nctId":"NCT06457464","phase":"","title":"Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-07-01","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT02586038","phase":"PHASE2","title":"STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS","status":"COMPLETED","sponsor":"Mario Boccadoro","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":175},{"nctId":"NCT02891811","phase":"PHASE2","title":"Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2017-03-10","conditions":"Multiple Myeloma","enrollment":124},{"nctId":"NCT03411031","phase":"PHASE2","title":"Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-10-04","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT04941937","phase":"PHASE2","title":"Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM","status":"UNKNOWN","sponsor":"Juan Du","startDate":"2022-01-27","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT01242267","phase":"PHASE1, PHASE2","title":"Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2010-05-11","conditions":"Multiple Myeloma","enrollment":29},{"nctId":"NCT00054158","phase":"PHASE2","title":"Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2004-08","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":24},{"nctId":"NCT05561049","phase":"","title":"Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-10-01","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":120},{"nctId":"NCT01849783","phase":"PHASE2","title":"Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Margarida Magalhaes-Silverman","startDate":"2013-04-04","conditions":"Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease","enrollment":41},{"nctId":"NCT02424851","phase":"PHASE2","title":"Optimising Renal Outcome in Myeloma Renal Failure","status":"COMPLETED","sponsor":"Oxford University Hospitals NHS Trust","startDate":"2014-11","conditions":"Multiple Myeloma, Chronic Kidney Disease","enrollment":31},{"nctId":"NCT00075829","phase":"PHASE3","title":"Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2003-12","conditions":"Multiple Myeloma","enrollment":710},{"nctId":"NCT00256776","phase":"PHASE3","title":"MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation","status":"TERMINATED","sponsor":"European Society for Blood and Marrow Transplantation","startDate":"2005-07","conditions":"Multiple Myeloma","enrollment":269},{"nctId":"NCT00792142","phase":"PHASE2","title":"Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2008-01-16","conditions":"Multiple Myeloma and Plasma Cell Neoplasm, Neurotoxicity","enrollment":45},{"nctId":"NCT02128230","phase":"PHASE2","title":"UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2014-06-10","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT04120519","phase":"PHASE2","title":"Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-10-10","conditions":"Langerhans Cell Histiocytosis","enrollment":20},{"nctId":"NCT00538733","phase":"PHASE2","title":"Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2007-10","conditions":"Multiple Myeloma","enrollment":26},{"nctId":"NCT04891744","phase":"PHASE1, PHASE2","title":"Selinexor in Combination With Thalidomide and Dexamethasone in RRMM","status":"UNKNOWN","sponsor":"Li Zheng","startDate":"2021-07-06","conditions":"Multiple Myeloma","enrollment":48},{"nctId":"NCT02545907","phase":"PHASE1, PHASE2","title":"A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis","status":"COMPLETED","sponsor":"University College, London","startDate":"2017-09-14","conditions":"Amyloidosis","enrollment":10},{"nctId":"NCT00907452","phase":"NA","title":"Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone","status":"COMPLETED","sponsor":"Intergroupe Francophone du Myelome","startDate":"2009-07-29","conditions":"Myeloma","enrollment":143},{"nctId":"NCT00966693","phase":"PHASE1, PHASE2","title":"Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-08-25","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":77},{"nctId":"NCT00274820","phase":"PHASE2","title":"Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2005-10","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes","enrollment":15},{"nctId":"NCT02733380","phase":"PHASE2","title":"Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2016-05","conditions":"Diffuse Large B-cell Lymphoma","enrollment":20},{"nctId":"NCT03608501","phase":"PHASE2","title":"A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2019-09-30","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT02410694","phase":"PHASE2","title":"Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2015-04","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT00689936","phase":"PHASE3","title":"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2008-08-21","conditions":"Multiple Myeloma","enrollment":1623},{"nctId":"NCT00452569","phase":"PHASE3","title":"Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2006-02-01","conditions":"Multiple Myeloma","enrollment":499},{"nctId":"NCT00657488","phase":"PHASE2, PHASE3","title":"Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2001-12-01","conditions":"Multiple Myeloma","enrollment":400},{"nctId":"NCT00049374","phase":"PHASE2","title":"Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2002-09","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT03393273","phase":"PHASE2","title":"Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-20","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT00124579","phase":"PHASE2","title":"S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2005-08","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT00064337","phase":"PHASE2","title":"S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2004-01","conditions":"Multiple Myeloma, Plasma Cell Myeloma","enrollment":104},{"nctId":"NCT01526694","phase":"PHASE2","title":"Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM","status":"COMPLETED","sponsor":"Azienda Ospedaliera di Bolzano","startDate":"2012-07","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT03562169","phase":"PHASE3","title":"The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)","status":"RECRUITING","sponsor":"University of Leeds","startDate":"2017-03-20","conditions":"Multiple Myeloma","enrollment":406},{"nctId":"NCT01554852","phase":"PHASE3","title":"Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2010-05","conditions":"Multiple Myeloma","enrollment":4420},{"nctId":"NCT03143036","phase":"PHASE2","title":"Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2018-05-01","conditions":"Relapse and / or Refractory Myeloma","enrollment":100},{"nctId":"NCT00538824","phase":"PHASE2","title":"Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2007-12","conditions":"Multiple Myeloma","enrollment":5},{"nctId":"NCT02559154","phase":"PHASE4","title":"Modified Bortezomib-based Combination Therapy for Multiple Myeloma","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2010-07","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT03402295","phase":"PHASE3","title":"Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation","status":"COMPLETED","sponsor":"Grupo de Estudos Multicentricos em Onco-Hematologia","startDate":"2009-06-15","conditions":"Multiple Myeloma, Effects of Chemotherapy","enrollment":311},{"nctId":"NCT01057225","phase":"PHASE1, PHASE2","title":"Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2010-03","conditions":"Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma","enrollment":64},{"nctId":"NCT00083915","phase":"PHASE3","title":"DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2001-06","conditions":"Multiple Myeloma","enrollment":97},{"nctId":"NCT00574080","phase":"PHASE3","title":"UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2006-07","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT03335098","phase":"PHASE2","title":"Study of VTD in Waldenstrom's Macroglobulinemia","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2016-11-21","conditions":"Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma","enrollment":15},{"nctId":"NCT03140943","phase":"PHASE2","title":"Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2017-09-13","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":100},{"nctId":"NCT02966522","phase":"PHASE2","title":"Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2016-10","conditions":"Cardiac Amyloidosis","enrollment":30},{"nctId":"NCT00081939","phase":"PHASE2","title":"UARK 2003-33, Total Therapy III","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2004-01","conditions":"Multiple Myeloma","enrollment":303},{"nctId":"NCT00113919","phase":"PHASE1, PHASE2","title":"UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2004-06","conditions":"Multiple Myeloma","enrollment":14},{"nctId":"NCT02248428","phase":"PHASE3","title":"Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma","status":"UNKNOWN","sponsor":"Jinling Hospital, China","startDate":"2012-04","conditions":"Multiple Myeloma","enrollment":130},{"nctId":"NCT00670631","phase":"PHASE2","title":"Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment","status":"COMPLETED","sponsor":"Guido Tricot","startDate":"2008-02","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT00222105","phase":"PHASE2","title":"A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2002-11","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT00182663","phase":"PHASE2","title":"Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2003-06","conditions":"Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma","enrollment":30},{"nctId":"NCT01548573","phase":"PHASE2","title":"Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment","status":"TERMINATED","sponsor":"University of Iowa","startDate":"2012-05","conditions":"Multiple Myeloma","enrollment":19},{"nctId":"NCT01133743","phase":"PHASE2","title":"Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2010-05","conditions":"Chronic Lymphocytic Leukemia","enrollment":31},{"nctId":"NCT01632150","phase":"PHASE2","title":"Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":51},{"nctId":"NCT00097981","phase":"PHASE3","title":"A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2005-01","conditions":"Multiple Myeloma","enrollment":225},{"nctId":"NCT02981199","phase":"NA","title":"Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"Chen Wenming","startDate":"2016-01","conditions":"Microtransplantation, Autologous Stem Cell Transplantation, Multiple Myeloma in Relapse","enrollment":80},{"nctId":"NCT00040937","phase":"PHASE2","title":"S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2002-06","conditions":"Multiple Myeloma","enrollment":147},{"nctId":"NCT00892346","phase":"PHASE3","title":"Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma","status":"SUSPENDED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2009-05","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT01976195","phase":"PHASE2","title":"High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP","status":"WITHDRAWN","sponsor":"Shandong University","startDate":"2013-10","conditions":"Immune Thrombocytopenia","enrollment":""},{"nctId":"NCT00450008","phase":"PHASE2","title":"Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer","status":"TERMINATED","sponsor":"The Methodist Hospital Research Institute","startDate":"2006-12","conditions":"Prostatic Neoplasms","enrollment":9},{"nctId":"NCT00458705","phase":"PHASE2","title":"Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-11","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":45},{"nctId":"NCT00083551","phase":"PHASE3","title":"UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"1998-08","conditions":"Multiple Myeloma","enrollment":668},{"nctId":"NCT00450801","phase":"PHASE2","title":"R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2004-04","conditions":"Lymphoma","enrollment":22},{"nctId":"NCT01971658","phase":"PHASE3","title":"Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2013-10","conditions":"Multiple Myeloma","enrollment":358},{"nctId":"NCT00111748","phase":"PHASE3","title":"UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2005-02","conditions":"Multiple Myeloma","enrollment":180},{"nctId":"NCT00057564","phase":"PHASE3","title":"A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene Corporation","startDate":"2003-02","conditions":"Multiple Myeloma","enrollment":470},{"nctId":"NCT00522392","phase":"PHASE3","title":"Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-09","conditions":"Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma","enrollment":48},{"nctId":"NCT00577096","phase":"NA","title":"Effects of Exercise in Combination With Epoetin Alfa","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2001-10","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT00723658","phase":"PHASE2","title":"S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2008-09","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT01055301","phase":"PHASE2","title":"S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2011-07","conditions":"Multiple Myeloma, Plasma Cell Myeloma","enrollment":""},{"nctId":"NCT00005834","phase":"PHASE3","title":"S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2000-04","conditions":"Multiple Myeloma","enrollment":19},{"nctId":"NCT00934739","phase":"PHASE2, PHASE3","title":"A Study of High-Risk Oral Cavity Cancer","status":"TERMINATED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2007-06","conditions":"Oral Cavity Cancer","enrollment":150},{"nctId":"NCT01537861","phase":"EARLY_PHASE1","title":"Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2012-06","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT00507416","phase":"PHASE3","title":"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2007-06","conditions":"Multiple Myeloma","enrollment":502},{"nctId":"NCT01246557","phase":"PHASE1, PHASE2","title":"Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatment","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2009-12","conditions":"Chronic Lymphatic Leukemia","enrollment":20},{"nctId":"NCT00033332","phase":"PHASE3","title":"Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-04","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT00205751","phase":"PHASE2, PHASE3","title":"Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy","status":"COMPLETED","sponsor":"Austrian Forum Against Cancer","startDate":"2001-08","conditions":"Multiple Myeloma","enrollment":350},{"nctId":"NCT00028886","phase":"PHASE3","title":"Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma","status":"UNKNOWN","sponsor":"Commissie Voor Klinisch Toegepast Onderzoek","startDate":"2001-03","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":450},{"nctId":"NCT00112879","phase":"PHASE2","title":"Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma","status":"WITHDRAWN","sponsor":"The Cleveland Clinic","startDate":"","conditions":"Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma","enrollment":""},{"nctId":"NCT00258245","phase":"PHASE1","title":"Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2005-05","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":5},{"nctId":"NCT00008242","phase":"PHASE2","title":"Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-08","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT00089167","phase":"PHASE2","title":"Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2002-05","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":202,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Thalomid","Baycadron","DexPak","Decadron"],"phase":"phase_3","status":"active","brandName":"Thalidomide plus dexamethasone","genericName":"Thalidomide plus dexamethasone","companyName":"Grupo de Estudos Multicentricos em Onco-Hematologia","companyId":"grupo-de-estudos-multicentricos-em-onco-hematologia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Thalidomide acts as an immunomodulatory agent and cereblon E3 ligase ligand, while dexamethasone provides corticosteroid-mediated anti-inflammatory and immunosuppressive effects. Used for Multiple myeloma (newly diagnosed or relapsed/refractory), Light chain myeloma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}